**ORIGINAL ARTICLE**

**Characterization of methicillin-resistant Staphylococcus aureus isolates from patients with persistent or recurrent bacteremia**

Henry Wong PhD,1 Christine Watt CMLT1, Sameer Elsayed MD FRCP2, Michael John MD FRCP2, Glen Johnson CMLT3, Kevin Katz MD FRCP4,5 Sigmund Krajden MD FRCP5,6 Christine Lee MD FRCP7, Tony Mazzulli MD FRCP5,8 Krystyna Ostrowska MD FRCP5,9 David Richardson MD FRCP10, Baldwin Toy MD FRCP11, Christie Vermeiren PhD4,5, Deborah Yamamura MD FRCP12, Andrew E Simor MD FRCP1,5

**BACKGROUND:** Methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections (BSI) are associated with considerable morbidity and mortality, especially with persistent (PB) or recurrent bacteremia (RB).

**OBJECTIVE:** To determine the frequency of PB and RB in patients with MRSA BSI, and to characterize the isolates from these patients.

**METHODS:** Surveillance for MRSA BSI was performed for one year in 13 Canadian hospitals. PB was defined as a positive blood culture that persisted for ≥7 days; RB was defined as the recurrence of a positive blood culture ≥14 days following a negative culture. Isolates were typed using pulsed-field gel electrophoresis (PFGE). Vancomycin susceptibility was determined using Etest.

**RESULTS:** A total of 183 patients with MRSA BSI were identified; 14 (7.7%) had PB and five (2.7%) had RB. Ten (5.5%) patients were known to have infective endocarditis, and five of these patients had PB or RB. Initial and subsequent MRSA isolates from patients with PB and RB had the same PFGE type. There were no significant differences in the distribution of PFGE types in patients with PB or RB (37% CMRSA-2/USA100; 37% CMRSA-10/USA300) compared with that in other patients (56% CMRSA-2/USA100; 32% CMRSA-10/USA300). All isolates were susceptible to vancomycin, but patients with PB or RB were more likely to have initial isolates with vancomycin minimum inhibitory concentration ≥ 2.0 µg/mL (26% versus 10%; P=0.06).

**CONCLUSIONS:** Persistent or recurrent MRSA bacteremia occurred in 10.4% of patients with MRSA BSIs. Isolates from patients with persistent or recurrent MRSA BSIs were more likely to exhibit reduced susceptibility to vancomycin, but not associated with any genotype.

**Key Words:** Bacteremia; Bloodstream infection; Methicillin-resistant Staphylococcus aureus; MRSA

**La caractérisation des isolats de Staphylococcus aureus résistant à la méthicilline chez les patients atteints de bactériémie persistante ou récurrente**

**HISTORIQUE:** Les infections sanguines (IS) par le Staphylococcus aureus résistant à la méthicilline (SARM) s’associent à une morbidité et une mortalité considérables, particulièrement en présence d’une bactériémie persistante (BP) ou récurrente (BR).

**OBJECTIF:** Déterminer la fréquence de BP et de BR chez les patients atteints d’une IS par le SARM et en caractériser les isolats.

**MÉTHODOLOGIE:** Les chercheurs ont surveillé les IS par le SARM dans 13 hôpitaux canadiens pendant un an. La BP se définissait par une hémothéculture positive qui persistait au moins sept jours, tandis que la BR désignait la récurrence d’une hémoculture positive au moins 14 jours après une hémoculture négative. Les chercheurs ont typé les isolats au moyen de l’électrophorèse sur gel en champ pulsé (ECP). Ils ont déterminé la susceptibilité à la vancomycine par Etest.

**RÉSULTATS:** Les chercheurs ont retracé un total de 183 patients ayant une IS par le SARM. De ce nombre, 14 (7,7%) avaient une BP et cinq (2,7%), une BR. Dix patients (5,5%) étaient atteints d’une endocardite infectieuse diagnostiquée, dont cinq avaient une BP ou une BR. Les isolats initiaux et subséquents de SARM chez les patients ayant une BP ou une BR présentaient le même type d’ECP. II n’y avait pas de différence significative dans la distribution des types d’ECP chez les patients ayant une BP ou une BR (37 % de souche CSARM-2/USA100; 37 % de souche CSARM-10/USA300) par rapport à celle des autres patients (56 % de souche CSARM-2/USA100; 32 % de souche CSARM-10/USA300). Tous les isolats étaient susceptibles à la vancomycine, mais les patients atteints d’une BP ou d’une BR étaient plus susceptibles de présenter des isolats initiaux de vancomycine dont la CMI = 2.0 µg/mL (26 % par rapport à 10 % ; P=0.06).

**CONCLUSIONS:** Les chercheurs ont observé une BP ou une BR par le SARM chez 10,4 % des patients atteints d’une IS par le SARM. Les isolats initiaux des patients atteints d’une IS persistante ou récurrente par le SARM risquaient davantage d’être moins susceptibles à la vancomycine, mais ne s’associaient à aucun gène.

**METHODS**

**Surveillance methods and definitions**

Thirteen hospitals in Ontario conducted prospective laboratory-based surveillance for MRSA bacteremia in adults (≥18 years of age) from January 1 to December 31, 2011. Persistent bacteremia was defined as MRSA bacteremia of ≥7 days duration (2,3). Recurrent MRSA bacteremia was defined as a recurrence of the bacteremia ≥14 days after documented negative blood cultures (4). Patients with infective endocarditis based on modified Duke’s criteria (8) were identified. Blood cultures were obtained at the discretion of the attending physician.

1Sunnybrook Health Sciences Centre, Toronto; 2London Health Sciences Centre, London; 3Lakeridge Health, Oshawa; 4Shared Hospital Laboratories; 5Department of Laboratory Medicine and Pathobiology, University of Toronto; 6St Joseph’s Health Centre, Toronto; 7St Joseph’s Healthcare, Hamilton; 8Mount Sinai Hospital, Toronto; 9Trillium Health Centre, Mississauga; 10William Osler Health System, Brampton;
11The Ottawa Hospital, Ottawa; 12Hamilton Health Sciences Centre, Hamilton, Ontario
Correspondence: Dr Andrew E Simor, Department of Microbiology, Sunnybrook Health Sciences Centre, B103-2075 Bayview Avenue, Toronto, Ontario M4N 3M5. Telephone 416-480-4549, fax 416-480-6990, e-mail andrew.simor@sunnybrook.ca

Can J Infect Dis Med Microbiol Vol 25 No 2 March/April 2014 ©2014 Pulsus Group Inc. All rights reserved 83
The study was approved with no requirement for patient consent by the Research Ethics Board, Sunnybrook Health Sciences Centre, (Toronto, Ontario).

Laboratory characterization of isolates
MRSA were typed using pulse-field gel electrophoresis (PFGE) following DNA extraction and digestion with Smal (9,10). PFGE-generated profiles were digitized and analyzed using BioNumerics software version 5.10 (Applied Maths, USA). Strains designated as CMRSA-10/USA100 resembled the major community-associated clone in North America (multilocus sequence type 8, clonal complex 8); CMRSA-2/USA100 resembles common health care-associated strains (sequence type 5, clonal complex 5). The staphylococcal chromosome cassette mec (SCCmec) was characterized (11) and the presence of the Panton-Valentine leukocidin (PVL) gene was assessed using polymerase chain reaction (12). Antimicrobial susceptibilities to vancomycin, daptomycin and linezolid were determined using Etest (bioMérieux Inc, USA). Susceptibility testing was also performed using broth microdilution on isolates with Etest vancomycin minimum inhibitory concentration (MIC) ≥2.0 µg/mL (13). Isolates with vancomycin MIC ≥1.5 µg/mL as determined by Etest were screened for the presence of heterogeneous intermediate resistance to vancomycin (hVISA) using the Etest GRD, as recommended by the manufacturer (bioMérieux Inc) (14,15).

Statistical analysis
Statistical analyses were performed using SPSS version 16.0 (IBM Corporation, USA). Patient-level and microbial characteristics from individuals with or without persistent or recurrent bacteremia were compared using Fisher’s exact test or the χ² test for categorical variables, and Student’s t test for continuous variables.

RESULTS
A total of 183 patients with MRSA bacteremia were identified during one year of surveillance. Sixty-nine (56.6%) were male and the median age was 64 years (range 18 to 96 years). All cases of bacteremia were monomicrobial. Fourteen (7.7%) patients had persistent MRSA bacteremia and five (2.7%) had recurrent bacteremia. Patients with persistent bacteremia were older (mean age 66.7 years) than those with recurrent bacteremia (mean age 46.2 years) (P=0.003). For individuals with persistent bloodstream infection, the median interval between the first and last positive blood cultures was 21 days, compared with 57 days for individuals with recurrent bacteremia. Infective endocarditis was identified in 10 (5.5%) patients: five (26.3%) with persistent or recurrent bacteremia, and five (3.0%) without persistent or recurrent bacteremia (P=0.007).

MRSA blood culture isolates from all patients with persistent or recurrent bacteremia and from 103 patients without persistent or recurrent bacteremia were available for laboratory characterization; results are summarized in Tables 1 and 2. Slightly more than one-half (53.3%) of the MRSA isolates recovered from bacteremic patients resembled health care-associated strains (CMRSA-2/USA100) as determined using PFGE. The second most common strain was a community-associated clone (CMRSA-10/USA300), accounting for nearly one-third (32.8%) of patients. In all patients with persistent or recurrent bacteremia, the PFGE type of subsequent blood culture isolates was identical to that of the initial bloodstream isolate, suggesting that all recurrences represented relapses. The distribution of PFGE and SCCmec types did not differ between isolates from patients with or without persistent or recurrent bacteremia. Isolates from 37 (30%) patients had the PVL gene; however, no association with persistent or recurrent bacteremia was observed.

Isolates resistant to vancomycin, daptomycin or linezolid were not detected. Two isolates (from patients with persistent/recurrent bacteremia) had vancomycin Etest MICs of 3.0 µg/mL. However, when tested using microbroth dilution, the MICs for these isolates were 1.0 µg/mL and 1.5 µg/mL. The MICs to vancomycin of initial and subsequent blood culture isolates in patients with persistent or recurrent bacteremia did not vary significantly (Table 2). Initial blood culture isolates with vancomycin MIC ≥2.0 µg/mL as determined using Etest were more often recovered from patients with persistent or recurrent bacteremia (26.3% versus 9.7%; P=0.06) (Table 1). There were six possible hVISA isolates identified using Etest GRD; however, this phenotype was not associated with persistent or recurrent bacteremia.

DISCUSSION
MRSA has been associated with a greater risk for persistent bacteremia than has methicillin-susceptible S. aureus, and persistence has been associated with worse outcomes (2,3,16). However, few studies have determined the frequency of persistent or recurrent MRSA bacteremia. In the present study, the rate of persistent MRSA bacteremia (7.7%) was similar to that reported previously (6.2% to 12.7%) (1,3). However, the rate of recurrent MRSA bacteremia (2.7%) appeared to be lower than that previously reported (10.6% to 31.8%) (1,4). The reasons for this variability in observed rates is uncertain, but may be related, in part, to differences in criteria used to determine persistence or recurrence, different thresholds for repeating blood cultures and variable patient populations included in the studies.

Several microbial characteristics have been associated with the development of persistent or recurrent MRSA bacteremia. MRSA isolates associated with persistent bacteremia were found to have agr locus dysfunction, and a reduced capacity to be killed in vitro by thrombin-induced platelet microbial protein (1). One study determined that MRSA with SCCmec type II were more likely to be associated with relapsing bloodstream infection (4). In the current study, neither SCCmec nor PFGE type was associated with persistence or recurrence; however, there were a relatively small number of patients with these complications.

Reduced susceptibility to vancomycin has frequently been reported to be associated with persistent and recurrent MRSA bloodstream infection (5-7). In the present study, we did not identify any strains that were resistant to vancomycin, and despite the relatively small numbers of patients with persistence or recurrence, we found that strains with a vancomycin MIC ≥2.0 µg/mL as determined using Etest...
TABLE 2
Characterization of methicillin-resistant Staphylococcus aureus (MRSA) bloodstream isolates in patients with persistent or recurrent bacteremia

<table>
<thead>
<tr>
<th>Patient (age, years)</th>
<th>Bloodstream infection</th>
<th>Interval between first and last positive blood culture, days</th>
<th>MRSA type (PFGE/SCCmec/PVVL)</th>
<th>Etest minimum inhibitory concentration, µg/mL</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 (76) Persistent + IE</td>
<td>21</td>
<td>CMRSA-10/IVa/−</td>
<td>1.5</td>
<td>1.5</td>
</tr>
<tr>
<td>2 (90) Persistent</td>
<td>18</td>
<td>CMRSA-2/II/−</td>
<td>0.75</td>
<td>1.0</td>
</tr>
<tr>
<td>3 (90) Persistent</td>
<td>186</td>
<td>CMRSA-2/II/−</td>
<td>2.0</td>
<td>2.0</td>
</tr>
<tr>
<td>4 (68) Persistent</td>
<td>9</td>
<td>CMRSA-2/II/−</td>
<td>1.5</td>
<td>2.0</td>
</tr>
<tr>
<td>5 (N/A) Persistent</td>
<td>12</td>
<td>CMRSA-10/IVa/−</td>
<td>1.0</td>
<td>1.0</td>
</tr>
<tr>
<td>6 (66) Persistent</td>
<td>27</td>
<td>CMRSA-2/II/−</td>
<td>1.5</td>
<td>2.0</td>
</tr>
<tr>
<td>7 (75) Persistent</td>
<td>17</td>
<td>Other/IV/−</td>
<td>0.38</td>
<td>0.38</td>
</tr>
<tr>
<td>8 (59) Persistent</td>
<td>96</td>
<td>CMRSA-10/IVa/−</td>
<td>1.5</td>
<td>2.0</td>
</tr>
<tr>
<td>9 (74) Persistent</td>
<td>19</td>
<td>CMRSA-2/IV/−</td>
<td>2.0</td>
<td>2.0</td>
</tr>
<tr>
<td>10 (74) Persistent</td>
<td>7</td>
<td>CMRSA-2/IV/−</td>
<td>1.0</td>
<td>2.0</td>
</tr>
<tr>
<td>11 (80) Persistent</td>
<td>9</td>
<td>Other/IV/−</td>
<td>2.0</td>
<td>2.0</td>
</tr>
<tr>
<td>12 (40) Persistent + IE</td>
<td>7</td>
<td>Other/IV/−</td>
<td>1.0</td>
<td>1.0</td>
</tr>
<tr>
<td>13 (20) Persistent + IE</td>
<td>9</td>
<td>CMRSA-10/IVa/−</td>
<td>1.0</td>
<td>1.0</td>
</tr>
<tr>
<td>14 (55) Persistent</td>
<td>63</td>
<td>CMRSA-2/II/−</td>
<td>3.0 (1.0)</td>
<td>1.5 (0.5)</td>
</tr>
<tr>
<td>15 (56) Recurrent</td>
<td>15</td>
<td>CMRSA-2/II/−</td>
<td>1.5</td>
<td>1.5</td>
</tr>
<tr>
<td>16 (46) Recurrent + IE</td>
<td>57</td>
<td>CMRSA-10/IVa/−</td>
<td>1.5</td>
<td>1.5</td>
</tr>
<tr>
<td>17 (33) Recurrent + IE</td>
<td>31</td>
<td>CMRSA-10/IVa/−</td>
<td>1.5 (0.5)</td>
<td>3.0 (1.5)</td>
</tr>
<tr>
<td>18 (56) Recurrent</td>
<td>25</td>
<td>CMRSA-2/II/−</td>
<td>1.0</td>
<td>1.0</td>
</tr>
<tr>
<td>19 (41) Recurrent</td>
<td>175</td>
<td>CMRSA-2/II/−</td>
<td>3.0 (1.0)</td>
<td>1.5 (0.5)</td>
</tr>
</tbody>
</table>

*Minimum inhibitory concentrations determined using broth microdilution in parentheses. IE Infective endocarditis; N/A Information not available; PFGE Pulsed-field gel electrophoresis; PVL Panton-Valentine leukocidin; SCCmec Staphylococcal cassette chromosome mec.

were more likely to be associated with persistent or recurrent bacteremia (Table 1). hVISA strains have also been associated with persistent or recurrent MRSA bacteremia in some (17-19), but not all, studies (20,21). These different results may be due to variability in the methods used to detect hVISA (19). In the present study, there were too few isolates that may have been hVISA to determine whether this phenotype is associated with persistent or recurrent bacteremia.

Laboratory-based surveillance involving every diagnostic laboratory in Ontario (population approximately 12.8 million) identified 560 patients with MRSA bloodstream infection in 2011 (an increase of 13% from the previous year), and MRSA represented 17% of all S. aureus isolated from blood cultures (22). Our study included nearly one-third (32.7%) of these patients. In this cohort, persistent or recurrent bacteremia occurred in 10.4% of patients. Important study limitations include the lack of available clinical, treatment or outcome data; in addition, the length of follow-up for these patients was variable. Because cultures were obtained at the discretion of the attending physician, cases with recurrent or persistent bacteremia may have been missed or misidentified. The small number of patients with persistent or recurrent infection may have precluded the ability to detect microbial characteristics associated with these complications. However, the present study does confirm an association between reduced susceptibility to vancomycin (as determined using Etest) and the development of persistent or recurrent MRSA bacteremia. Additional studies are required to better understand the clinical and microbial factors associated with these important complications.

ACKNOWLEDGEMENTS: This work was supported, in part, by an investigator-initiated grant from Sunovion Pharmaceuticals Canada Inc.

DISCLOSURES: Dr Andrew Simor has received grant funding, served on Advisory Boards, and has received speaker fees from Sunovion Pharmaceuticals Canada Inc and Pfizer Canada Inc. Dr Krystyna Ostrowska has served on Advisory Boards and received speaker fees from Merck Canada and Pfizer Canada Inc. All other authors declare that they have no conflicts of interest.

REFERENCES